AbbVie : Phase 3 Study Of Skyrizi In Crohn’s Disease Meets All Primary And Secondary Endpoints
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – AbbVie (ABBV) presented positive results from the head-to-head Phase 3 SEQUENCE study that evaluated the efficacy and safety of risankizumab (Skyrizi, 600 mg intravenous [IV] at week 0, 4 and 8 and 360 mg subcutaneous [SC] starting at week 12 and every 8 weeks thereaf
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-80864706-af4bc38e94e34052a5106e15bf44b2a2.jpg "Benchmark Oils: Brent Crude, WTI, and Dubai")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-77294443-88c7023010c9410c933c8029b3931c91.jpg "Reasons to Avoid Long-Term Auto Loans")